Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibody engineering

M S Hayden1, L K Gilliland, J A Ledbetter

  • 1Department of Autoimmunity and Transplantation, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington, WA 98121, USA. Martha_S._Hayden@ccmail.bms.com

Current Opinion in Immunology
|April 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Amplification of the immune response by agonistic antibodies.

Immunology today·2014
Same author

NF-kappaB and the immune response.

Oncogene·2006
Same author

How does B cell depletion therapy work, and how can it be improved?

Annals of the rheumatic diseases·2005
Same author

Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34(+) progenitor cells during differentiation into antigen presenting cells.

The Journal of biological chemistry·2001
Same author

ICOS ligand costimulation is required for T-cell encephalitogenicity.

Clinical immunology (Orlando, Fla.)·2001
Same author

Overview of the Third International Workshop on Swine Leukocyte Differentiation Antigens.

Veterinary immunology and immunopathology·2001

Recombinant DNA technology enables rapid antibody engineering, creating novel bispecific antibodies for therapeutic applications. Advanced phage display techniques address challenges in antibody-based therapies.

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Immunology

Background:

  • Antibody engineering has been significantly advanced by recombinant DNA techniques.
  • Novel antibody formats, like bispecific antibodies, offer tailored functional properties for specific applications.
  • Phage display technology has opened new avenues in immunology and antibody engineering.

Purpose of the Study:

  • To highlight the revolutionary impact of recombinant techniques in antibody engineering.
  • To showcase the generation of novel antibody molecules, including bispecific antibodies.
  • To discuss the application of new techniques in addressing challenges in therapeutic antibody use.

Main Methods:

  • Rapid cloning, expression, and characterization of cDNA encoding antibody subunits.

Related Experiment Videos

  • Fusion to heterologous protein domains, chain shuffling, and inclusion of self-assembly motifs.
  • Phage display of peptides and proteins.

    • Main Results:

    • Generation of novel bispecific antibodies with designed functional properties.
    • Expansion of applications in immunology and antibody engineering through phage display.
    • Addressing limitations in the therapeutic use of antibodies.

    Conclusions:

    • Recombinant techniques have revolutionized antibody engineering, enabling the creation of sophisticated antibody therapeutics.
    • Phage display and related technologies are crucial for advancing antibody-based treatments.
    • These advancements promise to overcome existing hurdles in the clinical application of antibodies.